Cytologic DNA methylation for managing minimally abnormal cervical cancer screening results
TL;DR 摘要总结
DNA甲基化检测(CISCER)在宫颈癌筛查中的应用研究表明，该方法对轻微异常结果具有良好的鉴别能力。在1857名患者中，CISCER检测CIN3+的敏感性为74.9%，特异性为89.1%。阳性结果提示CIN3+风险为40.5%，阴性结果风险仅2.7%，可显著减少不必要的阴道镜检查转诊。
摘要 · Abstract
METHODS: In the cohort of the METHY2 and METHY3 screening studies of women undergoing opportunistic cervical cancer screening, cervical cytology samples were sent for high-risk human papillomavirus (hrHPV) DNA assays, cytologic pathology and methylation assays of PAX1/JAM3 (CISCER). This study evaluated the discriminative power of CISCER in managing women with minimally abnormal cervical cancer screening results for CIN3+. Absolute CIN3+ risks and colposcopy referrals within one screening round were calculated
RESULTS: A total of 1857 women with minimally abnormal cervical cancer findings had cervical histologic outcomes and were included in the analysis. In women with a minimally abnormal cervical cancer result, the sensitivity and specificity of CISCER was 74.9% (95% confidence interval [CI], 68.3%-81.4%) and 89.1% (95% CI 87.6%-90.6%) for detecting CIN3+. CISCER analysis discriminated well for minimally abnormal cervical cancer results, yielding a CIN3+ risk of 40.5% (95% CI 34.9%-46.2%) after a positive result and a CIN3+ risk of 2.7% (95% CI 2.0%-3.6%) after a negative result
CONCLUSIONS: In women with a minimally abnormal cervical cancer screening result, the CISCER provides excellent detection of CIN3+. The use of CISCER in women with a minimally abnormal cervical cancer screening result can lead to a substantial reduction in the number of direct colposcopy referrals.
发表单位
Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China
引用格式
Shang, X. et al. Cytologic DNA methylation for managing minimally abnormal cervical cancer screening results. Int J Gynaecol Obstet https://doi.org/10.1002/ijgo.70167 (2025) doi:10.1002/ijgo.70167.
文献海报 · Poster
在新窗口查看
* 海报为中英双语，标题双语对照显示；可在海报右上角切换 EN / 中文，语言自动适配当前页面。